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“Sometimes science is more art than science, Morty. A lot of people don’t get that” 
Rick Sanchez, “Rick and Morty” 
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Resumo 
Os antibióticos, mais do que qualquer outro fármaco, são responsáveis por melhorar a 
expectativa de vida do Homem. No entanto, com o aumento do número de estirpes 
multirresistentes aos antibióticos e a sua disseminação pelo planeta, a capacidade de 
tratamento de infeções bacterianas está afetada. Esta é uma preocupação mundial em 
matéria de saúde pública. A obesidade e as doenças metabólicas também são uma 
ameaça global à saúde, com 600 milhões de adultos e 100 milhões de crianças 
diagnosticadas como obesas. A obesidade aumenta a probabilidade de outras doenças 
ocorrerem, como doenças cardiovasculares, diabetes tipo 2, apneia do sono, cancro, 
osteoartrite e depressão. Infelizmente, ainda não existe uma abordagem farmacológica 
segura e eficiente para tratar da obesidade. Por isso, a luta contra estes dois problemas 
exige o reforço da procura de novos compostos. 
Novas moléculas bioativas são, frequentemente, encontradas em ambientes sub-
explorados, como habitats marinhos. Muitos animais marinhos já provaram ser 
reservatórios para tais moléculas. Certas evidencias apontam para que a origem das 
moléculas bioativas esteja nas comunidades microbianas que colonizam e interagem 
com esses animais. Em face ao exposto, o principal objetivo deste trabalho foi confirmar 
a capacidade bioativa de bactérias marinhas, otimizar a produção das suas moléculas 
bioativas, isolar e caracterizar as mesmas e elucidar os seus modos de ação. 
No decorrer deste trabalho, várias bactérias pertencentes aos filos Actinobacteria, 
Gammaproteobacteria e Firmicutes, previamente isoladas de esponjas marinhas 
provenientes da costa marinha de Portugal, foram avaliadas quanto à capacidade de 
produção de moléculas com propriedades antimicrobianas. Ensaios preliminares já 
tinham mostrado o potencial bioativo dessas bactérias, o qual foi confirmado. No 
entanto, ao testar as bactérias em vários ensaios, nenhuma bioatividade antimicrobiana 
foi detetada. Modificações feitas aos métodos de incubação, de extração e ensaios 
antimicrobianos não resultaram em bioatividade consistente. Quando o volume total de 
cultura extraído foi aumentado, bioatividade consistente foi obtida. Duas estirpes de 
Actinobacteria, Rhodococcus equi (# 91-36.1) e Microbacterium foliorum (# 91-36.2) 
demonstraram bioatividade contra Bacillus subtilis e Micrococcus luteus, e M. foliorum 
demostrou ainda atividade contra Chlamydia trachomatis. Nos ensaios de anti-
obesidade, uma Gammaproteobacteria, Pseudovibrio sp. (B02-61), e uma 
Actinobacteria, Microbacterium sp. (B02-79), induziram a redução da acumulação de 
lipídios em larvas de peixes-zebra (Danio rerio). Extratos de R. equi e M. foliorum foram 
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submetidos a cromatografia de permeação em gel com o intuito de isolar compostos 
ativos. Contudo nenhuma das frações recolhidas revelou bioatividade. 
Apesar de termos conseguido verificar que várias bactérias produziam moléculas 
bioativas, apesar de nem sempre de forma consistente, não foi possível, infelizmente, 
no tempo de realização deste trabalho, conseguir o isolamento dos princípios ativos. 
Este trabalho demonstrou o potencial bioativo de bactérias marinha e é o ponto de 
partida para explorar as bioatividades encontradas, em particular o potencial anti-
obesidade. 
Palavras-chave 
Bioquímica; Microbiologia; Actinobacteria; Gammaproteobacteria; Firmicutes; 
Antibióticos; Resistência a antibióticos; Agentes Patogénicos; Metabolismo secundário; 
Obesidade; Extração de moléculas bioativas; 
Abstract 
Antibiotics, more than any other drug, are responsible for the improvement of Human life 
expectancy. Nonetheless, as multi-drug resistance increases and spreads throughout 
bacterial populations our ability to treat bacterial infections becomes greatly weakened. 
This is a worldwide public health concern. Obesity and metabolic diseases are also a 
global health threat, with 600 million adults and 100 million children diagnosed as obese. 
Obesity also increases the likelihood of various diseases and conditions like 
cardiovascular diseases, type 2 diabetes, sleep apnea, cancer, osteoarthritis and 
depression. Unfortunately, a lack of an efficient and safe pharmacological approach to 
treat obesity still exists. As such, novel compounds must be found. 
Novel bioactive molecules are frequently found in underexplored environments, like 
marine habitats. Many marine animals have already proven to be reservoirs for such 
molecules. Evidences points to a microbial origin of these bioactive molecules present 
in the communities that colonize such animals. Based on the above referred, the main 
goal of this work was to confirm the bioactive capacity of marine bacteria, optimize the 
production of their bioactive molecules, isolate and characterize them and clarify their 
modes of action. 
Over the course of this work, several Actinobacteria, Gammaproteobacteria and 
Firmicutes bacteria, previously isolated from marine sponges off the coast of Portugal, 
were screened for the capacity to produce molecules with antimicrobial properties. 
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Preliminary assays proved the bioactive potential of these bacteria, which was confirmed 
in this study. However, when testing bacteria in several assays, no antimicrobial 
bioactivity was detected. Modifications made to the incubation, extraction and test 
methods resulted in no evidence of consistent bioactivity. When the total culture volume 
for extraction was increased, consistent bioactivity was obtained. Two Actinobacteria 
strains, Rhodococcus equi (#91-36.1) and Microbacterium foliorum (#91-36.2) were 
found to be bioactive against Bacillus subtilis and Micrococcus luteus. Additionally, M. 
foliorum showed activity against Chlamydia trachomatis. In the anti-obesity assays, one 
Gammaproteobacteria, Pseudovibrio sp. (B02-61), and one Actinobacteria, 
Microbacterium sp. (B02 79), induce the reduction of lipid accumulation in zebrafish 
larvae (Danio rerio). Gel permeation chromatography was attempted in extracts from R. 
equi and M. foliorum with the goal to isolate bioactive compounds. However, none of the 
fractions collected proved to be bioactive. 
Despite various bacteria having produced bioactive molecules, although not always 
consistently, it was not possible to achieve the isolation of the active principles, in the 
limited timeframe of this thesis. 
This work demonstrated the bioactive potential of some marine bacteria and is the 
starting point for exploring the bioactivities found and in particular, the anti-obesity 
potential. 
Keywords 
Biochemistry; Microbiology; Actinobacteria; Gammaproteobacteria; Firmicutes; 
Antibiotics; Antibiotic resistance; Pathogens; Secondary Metabolism; Obesity; Bioactive 
molecule extraction; 
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Introduction 
Antibiotics are a type of antimicrobial pharmaceutical drugs used in the treatment and 
prevention of bacterial infections, either by killing (bactericidal) or by inhibiting 
(bacteriostatic) the growth of bacteria and can range from broad spectrum, meaning that 
they can act on both Gram+ and Gram- bacteria, to narrow spectrum, drugs with limited 
activity primarily only useful against particular species of microorganisms (Taber & 
Thomas, 1997). Although exists evidence that some traditional medicines used mixtures 
with antimicrobial properties for the treatment of infections, with poultices using specially 
selected molds and plant material extracts (Forrest, 1982), it was only in the late 
nineteenth and early twentieth centuries that laboratorial observations of antagonistic 
interactions between microorganisms led to the discovery of natural antibacterial 
compounds produced by microorganisms and the appearance of the concept of 
antibiosis, to describe the action of the metabolites produced in by microorganisms 
(Foster & Raoult, 1974). 
The history of antibiotics 
In the late 1880s in Germany, Paul Ehrlich noted that certain dyes would color human, 
animal, or bacterial cells, whereas others did not, and proposed the idea that it might be 
possible to create chemicals that would act as a selective drug that would bind to and kill 
bacteria without harming the human host. After screening hundreds of dyes against 
various organisms, in 1907, he discovered a medicinally useful drug, the first synthetic 
antibacterial arsphenamine, used in the treatment of syphilis (Schwalbe et al., 2007). 
This was the beginning of synthetic antibiotic chemotherapy, which delivered other useful 
drugs such as the first sulfonamides, Prontosil was developed by Bayer in 1935 from 
coal-tar dyes (Hager, 2006). Nevertheless, it was only with the discovery of penicillin in 
1928 by Alexander Fleming that antibiotics started to revolutionize humanity in the 20th 
century. Penicillin displayed potent antibacterial activity against a wide range of bacteria, 
had low toxicity in humans, was not inhibited by biological constituents such as pus and 
could be mass-produced in World War II, helping with casualties (Florey, 1945; Sykes, 
2001). The discovery of such a powerful antibiotic was unprecedented, and, in 
conjunction with other antibiotics and vaccination, near eradication of some diseases 
was achieved. Nonetheless, almost all compounds with antimicrobial activity were 
discovered between the 1920s and the 1960s in the golden age of antibiotics. 
Afterwards, innovation came mainly though derivatives of the previously discovered 
compounds (Lewis, 2013). 
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How do antibiotics work 
Antibiotics work by disrupting key biological processes in the bacterial cell, ranging from 
inhibiting enzymes or interfering with other cellular components through the disruption of 
essential cellular processes like the synthesis of cell wall, nucleic acid and proteins. The 
specific biochemical interaction between the antibacterial compound and its biological 
target to produce the disruption of the biological process are known as the mechanisms 
of action (Spratto & Woods, 2012). 
As such, antibiotics can be either divided into two categories, broad and narrow-
spectrum action, or into more specific groups, that specify the target of the antibacterial 
compounds action. Broad-spectrum antibiotics, act against a wide range of bacteria 
normally both Gram+ and Gram- bacteria (Taber & Thomas, 1997). An example of 
antibiotics in this category is ampicillin. Ampicillin is part of the β-lactam family of 
antibiotics, like penicillin G. Ampicillin, unlike this, can penetrate Gram+ and some Gram- 
bacteria, as it has an amino group that helps the drug in the penetration of the outer 
membrane. This allows the normal action of the β-lactam antibiotics, stopping the 
enzyme that catalyzes the transpeptidation that crosslinks the peptide side chains of 
peptidoglycan strands. This action prevents normal cell wall regeneration and leads to 
cell lysis (Goodman et al., 2006). Narrow-spectrum antibiotics, as the name implies, are 
active against a selected group of bacterial types and as such, are only typically used for 
specific infections when the bacterium is known. This selectivity also means that 
resistance is less likely to emerge. An example is fusidic acid, a steroid antibiotic active 
mainly against Gram+ bacteria, that works by inhibiting bacterial protein synthesis (Rang 
et al., 2015). 
Nonetheless, this nomenclature provides almost no information about the underlying 
mechanisms behind their function and, as such, antibiotics are primarily divided into four 
main groups: inhibitors of cell wall synthesis, inhibitors of DNA synthesis, inhibitors of 
RNA synthesis and inhibitors of protein synthesis (Kaufman, 2011; Rang et al., 2015). 
Many of these are part of the Class III and Class II biochemical reactions. 
Unlike eukaryotes, prokaryotes possess a cell wall with peptidoglycan, and this makes 
the bacterial cell wall an ideal target for antibiotic compounds to act, since these should 
only affect prokaryote cell and not eukaryotes. Therefore, inhibitors of cell wall synthesis 
will prevent components of the bacterial machinery responsible for the cell wall 
regeneration from working appropriately. For example, penicillin and other β-lactams 
interrupt peptidoglycan synthesis by binding to the proteins from the penicillin-binding 
proteins (PBPs) group. These have been shown to catalyze several reactions involved 
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in the process of synthesizing cross-linked peptidoglycan from lipid intermediates and 
mediating the removal of D-alanine from the precursor of peptidoglycan (Basu et al., 
1992). This results in the formation of a weak or deformed cell wall, which swells and 
bursts (Rang et al., 2015). 
DNA replication and cell division are fundamental in maintaining and produce new 
bacterial cells. As such, some antibiotics can work by inhibiting replication of DNA. 
Interference with nucleic acid synthesis is possible in four different ways, by disruption 
of the DNA chains, inhibition of the synthesis of nucleotides, altering the base-pairing 
properties of the DNA template or inhibiting DNA gyrase, which uncoils supercoiled DNA 
to allow transcription (Kaufman, 2011). Disruption of DNA can be difficult to achieve, as 
it could affect eukaryotic cells besides prokaryotic ones. For this reason, drugs that act 
by disruption of DNA only work in very specific conditions. This is the case of 
metronidazole, which though reduction of its nitro group leads to the production of the 
short-lived cytotoxic intermediates that then interact with DNA, leading to cell death 
(Muller, 1983). Inhibition of the synthesis of the nucleotides can be accomplished by an 
effect on the metabolic pathways that generate nucleotide precursors. The folate 
biosynthetic pathway, that is only found in bacteria but not in humans, is an example. 
Folate is required for DNA synthesis in both bacteria and in humans, but humans must 
obtain it from the diet and concentrate it in cells by specific uptake mechanisms, while 
most species of bacteria lack these essential transport mechanisms and need to 
therefore synthesize it de novo. Sulfonamides are structural analogs of para-
aminobenzoic acid (PABA), an essential component in the synthesis of folate, and 
compete with PABA for the enzyme dihydropteroate synthetase, and thus inhibit bacterial 
growth without impairing mammalian cell function (Rang et al., 2015). Alteration of the 
base-pairing properties of the template agents act by intercalating in the DNA and 
causing frameshift mutations or mispairing. Examples of these agents include acridines, 
that double the distance between adjacent base pairs causing frameshift mutations, 
while inhibitors of DNA gyrase like fluoroquinolones act by selectively inhibiting the 
topoisomerase II ligase domain, which leads to fragmentation of DNA and cell death 
(Suto et al., 1992). 
Besides the three ways described above, DNA polymerase III inhibitors like anilinouracils 
are being developed. These are analogs of uracil that cannot form the 5’-3’ links between 
nucleotides, halting DNA elongation and also sequestering DNA polymerase III with high 
affinity ternary complexes, eventually leading to cell lysis (Svenstrup et al., 2008; 
Tarantino et al., 1999). 
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Inhibition of RNA synthesis has a catastrophic effect on prokaryotic nucleic acid 
metabolism and is a potent means for inducing bacterial cell death. Specific inhibitors of 
bacterial RNA polymerase like rifampicin act by binding to RNA polymerase during the 
formation of the first two phosphodiester bonds and blocking the translocation step that 
would follow (McClure & Cech, 1978). 
Both eukaryotes and prokaryotes require de novo protein synthesis as to maintain 
normal cellular functions, which in both happens in the cytosol, when mRNA is translated 
into an aminoacidic chain, on the ribosomes in a three-step process (Initiation, 
Elongation and Termination). Ribosomes also have three binding sites for tRNA, that 
transfer amino acids to ribosome, labelled the A, P and E sites. However, eukaryotic and 
prokaryotic ribosomes are structurally different which provides the basis for selective 
antimicrobial action of some antibiotics (Rang et al., 2015). The bacterial ribosome 
consists of a 50S subunit and a 30S subunit, which combine into a 70S when mRNA is 
attached to the 30S subunit, unlike the eukaryote subunits are 60S and 40S (Ben-Shem 
et al., 2011). Inhibition of mRNA translation can be achieved by inhibitors of 50S subunit 
or inhibitors of 30S subunit. 50S ribosome inhibitors include the macrolides, 
lincosamides, streptogramins, amphenicols and oxazolidinones and in general terms 
work by blocking either initiation of protein translation or translocation of tRNA, inhibiting 
the peptidyltransferase reaction (Kohanski et al., 2010). However, 30S ribosome 
inhibitors like the tetracyclines and aminoglycosides, can disrupt the 30S ribosome in 
either of two ways. Tetracyclines compete with tRNA by blocking access of aminoacyl-
tRNAs to the ribosome or by interacting with the 16S component of the 30S subunit that 
leads to instability of the connection between tRNA and ribosomes. Aminoglycosides 
cause an alteration in the conformation of the complex formed between an mRNA codon 
and its cognate charged aminoacyl-tRNA at the ribosome and promote tRNA 
mismatching (Kohanski et al., 2010; Rang et al., 2015). 
Molecular mechanisms of antibiotic resistance 
As most natural antibiotic compounds are secondary metabolites that bacteria use to 
outcompete others for resources, resistance to these compounds has evolved in specific 
species and strains, which means that intrinsic resistance precedes medical use of 
antibiotics (D'Costa et al., 2011). Widespread use and misuse of antibiotics after World 
War II are due to wider global availability, uncontrolled sale, their use in livestock feed at 
low doses for animal growth promotion (Ferber, 2002) and release of large quantities of 
antibiotics into the environment during pharmaceutical manufacturing through 
inadequate wastewater treatment have caused evolutionary pressure on bacteria 
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(Ventola, 2015), resulting in a selective pressure of bacteria that lead to a spreading of 
resistance mechanisms throughout populations. 
Essentially there are three key mechanisms by which bacteria become resistant to 
antibiotics: drug inactivation or modification, reduced drug accumulation and alteration 
of target site (Hawkey, 1998). In inactivation or modification of the antibiotic compound, 
the resistant bacteria retain the same sensitive target as antibiotic sensitive strains, but 
the antibiotic is prevented from reaching it. An example is the resistance to β-lactams, in 
which β-lactamases enzymatically cleave the four membered β lactam ring, rendering 
them inactive (Livermore, 1995). Reducing drug accumulation in the cell is another 
method bacteria have developed to prevent cell death. This can be achieved either 
thought an efflux pump, which pumps the antibiotic out of the cell, or inactivation of the 
original transporter responsible for the influx of the antibiotic (Hawkey, 1998). A case of 
this kind of resistance, is the lack of effect of β-lactams in Pseudomonas aeruginosa 
which has been found to lack a specific porin in the cell membrane, impeding β-lactams 
from entering the cell (Livermore, 1984). Pseudomonas aeruginosa has also been found 
to have a very efficient active efflux for tetracyclines, chloramphenicol and norfloxacin, 
which also explains this organism’s general resilience (Li et al., 1994). Bacteria, due to 
their fast division cycle and lack of many DNA repair mechanisms, tend to accumulate 
mutations fairly quickly (Martinez & Baquero, 2000), and can even integrate foreign DNA 
into their chromosome (Pozzi & Guild, 1985). These characteristics can be beneficial in 
achieving resistance to an antibiotic compound, as it may alter a target site in such a way 
that the antibiotic becomes unable to produce its effect. Most strains of Streptococcus 
pneumoniae are susceptible to β-lactams, but can acquire DNA from other bacteria with 
penicillin-binding proteins (PBPs) that have less affinity for penicillin (Zighelboim & 
Tomasz, 1980). Hence the altered PBPs still synthesize peptidoglycan for the cell wall, 
but are no longer susceptible to inhibition by β-lactams (Hawkey, 1998). 
Consequences for the future 
Since 2014, the World Health Organization (WHO) releases yearly reports on the global 
rise of resistance in pathogenic bacteria and a list of priorities on the need of new 
research. The Global Antimicrobial Resistance Surveillance report, released in April 
2014, foresees an alarming future for mankind, since, for example, in patients with third-
generation cephalosporin resistant Escherichia coli infections there was a two-fold 
increase in mortality attributable to bacterial infection and in patients with Methicillin-
Resistant Staphylococcus aureus (MRSA) infections there was also a significant 
increase in bacterial attributable mortality (WHO, 2014). These bacteria are some of the 
most common among humans. S. aureus colonizes the anterior nares (external portion 
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of the nostrils) while E. coli forms part of the gut microbiome (Eckburg et al., 2005) and 
are a cause of the most common bacterial infection, such as urinary tract infections, food 
poisoning and bacteremia or blood poisoning (Brown et al., 2014; Vogt & Dippold, 2005). 
And the latest pathogen priority list, released in the 27th of February 2017, that does not 
include Mycobacteria, which has its own report, places various Gram- bacteria, such as 
Acinetobacter baumannii, Pseudomonas aeruginosa and various Enterobacteriaceae 
(all of them resistant to carbapenems) as the top priorities for research and development 
of new drugs. Most antibiotics discovered in the past century were done so by screening 
soil microorganisms, but this limited resource of cultivable bacteria has already been 
over-explored, and synthetic approaches to produce antibiotics have not been able to 
replace them (Lewis, 2013). Unfortunately, these and other obstacles, like economic and 
regulatory ones, have made big pharmaceutical companies heavily reduce the 
investment in the field, making academia the main drive for the development of new 
compounds (Bartlett et al., 2013; Gould & Bal, 2013; Ventola, 2015). This means that 
discovery and development of new antibiotics, specifically active against multidrug Gram- 
bacteria, and in particularly members of the Enterobacteriaceae family, such as 
Klebsiella pneumonia and E. coli, have been severely hampered. All these factors 
combined led to the production of several scientific review papers that showed haunting 
predictions for the future. In one of these it is expected that by the year 2050, mortality 
due to resistant bacterial infections would surpass deaths by cancer, the todays “in 
vogue” disease and worldwide costs in the trillions of dollars of gross domestic product 
(The Review on Antimicrobial Resistance, 2014). 
New sources of potential antimicrobials. 
Despite this seemingly apocalyptical prevision for the future, we still hold two major 
reserves of untapped producers of interesting bioactive molecules. New techniques, like 
the now famous iChip (Nichols et al., 2010), have allowed previously unculturable soil 
bacteria to be screened for production of antimetabolites of interest (Piddock, 2015). 
These previously unculturable bacteria are assumed to account for 99% of the soil 
microbiome and they are now expected to provide interesting new leads (Pham & Kim, 
2012). 
Besides uncultured soil bacteria, marine organisms, and in particular sponges, have also 
been providing interesting compounds. Already several drugs have been described, 
namely Xestospongin C, an inhibitor of the inositol 1,4,5-triphosphate (IP3) receptor 
(Miyamoto et al., 2000) and Manoalides, a set of terpenoid compounds that has shown 
potential as biofilm modulators (Stowe et al., 2011). Sponges show a great diversity in 
their microbiological communities, often showing both the presence of Archaea, Fungi, 
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microalgae and a great diversity of bacterial phyla (Webster et al., 2001), with evidences 
showing that these interactions started over 600 million years ago (Wilkinson, 1984). 
Unfortunately, sponges may only contain minute quantities of these compounds in their 
body. For example, in Lissodendorix sp., halichondrin B only exist in a concentration of 
400 μg/kg (Sipkema et al., 2005). This makes it impractical for clinical trials due to the 
need to collect vast amounts of marine organisms to isolate the amount of compound 
necessary to conduct these trials well as for commercialization. Interestingly, several 
studies point to the symbiotic bacteria as the true origin of these compounds. This opens 
the possibility of isolating and cultivating producing symbionts, thus insuring a sufficient 
and constant supply of the bioactive molecules and this relationship has already revealed 
interesting compounds (Yoo Kyung et al., 2001). One such example is Alteramide A, 
which was isolated from an Alteromonas sp. symbiont of a sponge specimen of 
Halichondria okadai off the coast of Nagai, Japan and is a macrocyclic lactam with 
powerful cytotoxic effect on murine leukemia P388 cells, murine lymphoma L1210 cells 
and human epidermoid carcinoma KB cells (Shigemori et al., 1992). Besides sponges, 
other marine animals have also provided bacteria with valuable compounds. An example 
of this is Tauramamide, a new lipopeptide with antimicrobial characteristics that was 
extracted from the isolate Brevibacillus laterosporus PNG276 obtained from an 
unidentified tubeworm collected off the coast of Loloata Island in Papua New Guinea and 
showed a broad-spectrum antibiotic activity, inhibiting both MRSA and Vancomycin-
resistant Enterococcus (Desjardine et al., 2007). 
Actinobacteria: complex with interesting secondary metabolism 
The Actinobacteria phylum is one of the largest taxonomic units among the 18 major 
lineages currently recognized within the domain Bacteria, including 5 classes and 14 
orders. Actinobacteria are Gram+ bacteria, meaning that they stain violet with Gram 
staining and have a thick peptidoglycan layer. Additionally, Actinobacteria possess a high 
Guanine/Cytosine ratio (G+C ratio) in their DNA, which can range from 51 to 70% 
(Lechevalier & Lechevalier, 1967). Morphologically, Actinobacteria can exhibit a wide 
range of forms, from coccoid or rod-coccoid to fragmenting hyphal forms or permanent 
and highly differentiated branched mycelium (Atlas, 1997). Ecologically, they are present 
in all ecosystems, be they terrestrial or aquatic and can act both in the carbon cycle and 
nitrogen cycle, either by helping decomposing organic matter such as the 
Actinomycetales or fixing nitrogen in the symbiotic relationship with plant roots like 
Frankia (Goodfellow & Williams, 1983). Additionally, Actinobacteria can be both 
symbionts, such as Bifidobacterium or pathogens, like Mycobacterium and Nocardia 
(Schell et al., 2002; Wilson, 2012). 
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Besides all these characteristics, Actinobacteria are also prolific producers of bioactive 
metabolites, with emphasis on species and strains belonging to the Actinomycetales, 
most notably the Streptomyces genus. There is a total of fifteen antibacterial 
pharmaceutical agents still in use that were obtained from Streptomyces. Besides the 
staggering number of antimicrobials, several anti-fungal, anti-parasitic, herbicides and 
pesticides have their origin in this genus (Mahajan & Balachandran, 2012). This unusual 
density of useful compounds is attributed to two characteristics of Actinobacteria: their 
big genome and high G+C content ratio. A high G+C ratio is indicative of a higher number 
of coding DNA, since A+T are biased towards stopping codons. An example is S. 
coelicolor that possesses 7825 protein coding genes which includes over twenty gene 
clusters for the synthesis of known or predicted natural products (Bentley et al., 2002). 
Already four antimicrobial compounds were isolated from this bacterium, including 
undecylprodigiosin and perimycin (Brian et al., 1996; Lee & Schaffner, 1969). 
Polyketide synthases and non-ribosomal peptide synthetases 
Most of the biosynthesized compounds of interest have their roots in two groups of 
enzymes, the polyketide synthases (PKS) and non-ribosomal peptide synthetases 
(NRPS). So, the presence of these genes in newly discovered organisms or strains can 
indicate the possibility of discovering a new interesting bioactive molecule (Donadio et 
al., 2007). 
PKSs are a family of enzyme complexes that produce polyketides, a common class of 
secondary metabolites, by catalyzing, almost as a molecular LEGO set, linear carbon 
extensions in simple two, three and four carbon building blocks and keto-group 
processing reactions, that share a great similarity with fatty acid biosynthesis (Dutta et 
al., 2014). They are classified in three different sets. Type I PKS are large, highly modular 
proteins, that further subdivide in to two other categories. Iterative PKS are composed of 
several monofunctional or bifunctional proteins and Modular PKS contain a sequence of 
separated modules with unique domains of 100 to 400 amino acids in size, responsible 
for one cycle of polyketide chain extension and functional group modification (Khosla et 
al., 1999). While Type I PKS are predominantly found in Actinobacteria, Myxobacteria, 
Pseudomonades Cyanobacteria and more recently in Planctomycetes (Bode & Muller, 
2005; Graca et al., 2016), Iterative PKS are typically found in Fungi (Cox & Simpson, 
2009). Type II PKS are multienzyme complexes of discrete proteins only found in 
bacteria (Shen, 2000). Type III PKS are found in bacteria, fungi and plants and their main 
characteristic is that Type III PKS do not use the Acyl Carrier Protein (ACP) (Jenke-
Kodama et al., 2005; Yu et al., 2012), an important carrier of acyl intermediates in both 
fatty acid and polyketide biosynthesis that exhibit characteristic structural features of 
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natively unfolded proteins in vitro with a thioester-linked acyl group attached to a 4’-
phosphopantetheine (Byers & Gong, 2007). 
PKSs genes in bacteria, are usually organized in a single operon with modules featuring 
common domains such as the ACP, already discussed above, the Acyltransferase, and 
Keto-synthase domains. Additionally, other domains such as Dehydratase, Enoyl-
reductase, Keto-reductase, Methyltransferase, and Sulf-hydrolase and Thio-esterase 
can also be part of the biosynthetic pathway (Jenke-Kodama et al., 2005). 
Non-Ribosomal Peptide Synthetases (NRPS) are a cluster of modular enzymes that 
catalyze, through complex regiospecific and stereospecific reactions, important peptide 
products. NRPS synthesis, similarly to ribosomal protein synthesis, is divided into three 
steps, Initiation, Elongation and Termination. Despite these similarities, NRPSs are only 
limited by the length of the peptide chain, which is between two to forty-eight residues 
and can use a variety of standard and non-proteinogenic amino acids (amino acids that 
are not naturally encoded or found in the genetic code of any organism) (Strieker et al., 
2010). As with PKSs, NRPSs in bacteria are also organized in a single operon with 
different modules featuring common domains. There are four ubiquitous domains to all 
NRPSs, Adenylation domains, Peptidyl Carrier Protein (PCP) domains, Condensation 
domains and the Thioesterase domain. The Thioesterase domain is only found at the 
termination module and is responsible for the release of the peptide by hydrolysis or 
macrocyclization (Kopp & Marahiel, 2007). Other domains include Formylation, 
Cyclization, Oxidation, Reduction, Epimerization and N-methylation (Miller & Gulick, 
2016). In the Initiation step, adenylation of the amino acids though ATP hydrolysis 
occurs, forming an unstable intermediate, that is subsequently transferred to another site 
of the enzyme where it is bound as a thioester to the cysteamine group of an enzyme-
bound 4′-phosphopantetheinyl that forms the backbone of the PCP (Marahiel et al., 1997; 
Miller & Gulick, 2016). In the next step, Elongation, the condensation domain catalyzes 
the peptide bond between the thioester group of the growing peptide chain downstream 
from the PCP to another PCP-bound amino acid upstream. It is also during this step that 
another reaction catalyzed by the non-essential domains may occur. Lastly, the 
Termination stage finishes biosynthesis by releasing the completed polypeptide from the 
PCP domain from the last module (Kopp & Marahiel, 2007). 
Combating obesity 
As obesity is continuing to rise, it has become the most prevalent metabolic disease in 
the devolved and developing nations, contributing to an enormous rise in other 
associated diseases such as diabetes, cardiovascular disease and even cancer (Castro 
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et al., 2016). Obesity, defined as a body mass index (BMI) above thirty kg/m2, is primarily 
caused by a disproportion of intake and spending of calories. As recommended by the 
WHO and many other experts, fighting obesity has to start at the personal level with 
reduction of the energy intake from high calorie fats and sugars and an increase in 
exercise, accompanied by the reduction of the level of fats and sugars added by the food 
industry to their products (Allan, 2004). 
Unfortunately for some patients these recommendations alone may not work, and for 
these medication is required. Current treatment works primarily by two different 
mechanisms of action, appetite suppression and interference with the body’s ability to 
absorb specific nutrients (e.g. fats). Appetite suppressants work by exploiting the action 
or production of neuroendocrine satiety signals such as Cholecystokinin, which is 
secreted by the duodenum in response to the process of eating and digestion, to reduce 
meal size and frequency. The drugs most commonly used for this are catecholamines 
like amphetamines and anti-depressants like bupropion (Bray, 1993). A glucagon-like 
peptide, liraglutide is being trialed as to ascertain its ability to do just this (Rang et al., 
2015). To inhibit the absorption of fat, orlistat is usually recommended, which is an 
inhibitor of enzyme lipase causing fat malabsorption in the intestine. Orlistat is derived 
from lipstatin, a bioactive molecule first isolated from the Actinobacteria, Streptomyces 
toxytricini (Weibel et al., 1987). Orlistat is generally considered safe and is replacing 
many centrally acting appetite suppressants, which have been reported to cause series 
of adverse effects, like addiction and pulmonary hypertension (Rang et al., 2015). 
Regrettably, many of these pharmacological approaches to treat obesity seem to fall 
short, as a meta-analysis by Viner and colleagues seems to indicate that orlistat together 
with behavioral support has limited utility as a weight reduction treatment in adolescents, 
producing a small effect with frequent gastrointestinal side effects (Viner et al., 2010). 
Research on the stilbene 3,5,4′-trihydroxy-trans-stilbene, also named Resveratrol, has 
provided new leads to treat obesity. Dietary calorie restrictions on mammals was known 
to, not only reduce body mass, but also restore insulin sensitivity and increasing lifespan 
(Koubova & Guarente, 2003). The mechanism through which these actions occurred was 
later discovered to be the result of the activations of the silent mating type information 
regulation 2 homolog 1 (SIRT1) protein, that caused fat mobilization and had a role in 
the protection on oxidative stress (Lin et al., 2000) and inhibition of the inflammation 
factor nuclear factor kappa B (NF-kB) (Franceschi & Campisi, 2014). Resveratrol was 
found to reduce the synthesis of lipids in rat liver (Arichi et al., 1982) and 3T3-L1 
adipocytes (Picard et al., 2004), by activation SIRT1 proteins and mimicking the effects 
of calorie restriction (Howitz et al., 2003). Resveratrol, given as dietary supplement, could 
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reproduce this effects on mice (Lagouge et al., 2006). Regrettably, Resveratrol seems 
not to show any effect on humans. In a randomized placebo-controlled, double-blinded, 
and parallel-group design trial, 24 obese men were given high doses of Resveratrol, with 
no effect on blood pressure, resting energy expenditure, oxidation rates of lipid, ectopic 
or visceral fat content and no change in inflammatory and metabolic biomarkers (Poulsen 
et al., 2013). Another study seems to confirm this same result, with the authors stating 
that Resveratrol lacked any adjuvant effect on energy restriction for obesity treatment 
purposes (Alberdi et al., 2014). New anti-obesity drugs are thus still needed to fight 
against a more and more “fat” society. 
Objectives 
With this Master’s Thesis, developed in the Laboratório de Ecofisiologia Microbiana da 
Universidade do Porto (LEMUP-CIIMAR), in Porto, Portugal and in conjunction with the 
Institut für Pharmazeutische Mikrobiologie Universität Bonn, in Bonn, Germany as part 
of the Erasmus+ Estágio program, we aimed to uncover more about the secondary 
metabolism of thirty-three bacteria isolated from sponges that previously showed signs 
of great potential for production of useful bioactive compounds, with particular emphasis 
in the search for new potential antimicrobials. To achieve this, we have attempted to 
extract any possible bioactive molecules with several different liquid-to-liquid extraction 
protocols allied with bio-guided assays and powerful bioanalytical techniques like liquid 
chromatography. 
Furthermore, the opportunity arose for the screening for the capacity to affect lipid 
metabolism and obesity of extracts from these bacteria to be also performed utilizing 
zebrafish (Danio rerio) larvae. 
Materials and Methods 
1. Biological material 
1.1. Bacterial strains and selection criteria used 
Based on previous studies conducted in Laboratório de Ecofisiologia Microbiana da 
Universidade do Porto (LEMUP), 17 Actinobacteria strains were selected, with 16 other 
strains (15 belonging to the phylum Gammaproteobacteria and 1 belonging to phylum 
Firmicutes) later added. The thirty-three strains were chosen either because of the 
presence of the PKS-I and/or NRPS gene clusters or for having showed prior 
antimicrobial activity against bacterial targets. All thirty-three strains were previously 
isolated and characterized (Table 1) (Graca et al., 2013; Graca et al., 2015). 
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Table 1 - Selected bacteria strains used for testing.  
Isolate Related strain Phylum 
PKS-I / 
NRPS 
Previous 
activity 
#91_17 Dermacoccus sp. Actinobacteria NRPS CA 
#91_29 Microbacterium foliorum Actinobacteria N/A CA 
#91_31 
Microbacterium 
hydrocarbonoxydans Actinobacteria N/A CA 
#91_34 
Microbacterium 
esteraromaticum Actinobacteria N/A CA 
#91_35 
Microbacterium 
phyllosphaerae Actinobacteria PKS-I CA; BS 
#91_36.1 Rhodococcus equi Actinobacteria PKS-I; NRPS CA; VA; EC 
#91_36.2 Microbacterium foliorum Actinobacteria N/A CA; VA 
#91_37 Microbacterium foliorum Actinobacteria N/A CA; VA 
#91_40 Microbacterium foliorum Actinobacteria PKS-I CA; VA 
SM 115 Agrococcus sp. Actinobacteria PKS-I NA 
SM 116 Agrococcus sp. Actinobacteria PKS-I NA 
B01-119c Microbacterium sp. Actinobacteria N/A VA; VF 
B02-22.2 Gordonia sp. Actinobacteria PKS-I BS 
B02-29 Gordonia sp. Actinobacteria N/A BS 
B02-78 Gordonia terrae Actinobacteria PKS-I; NRPS BS 
B02-79 Microbacterium sp. Actinobacteria N/A BS 
B02-79a Microbacterium sp. Actinobacteria N/A BS 
#118_14 Proteus mirabilis Gammaproteobacteria N/A CA; VA; EC 
#118_17 Psychrobacter celer Gammaproteobacteria N/A CA; VA; EC 
#118_20 Proteus sp. Gammaproteobacteria PKS-I CA; EC 
#118_19 Enterococcus faecalis Firmicutes PKS-I CA; VA; EC 
#91_10,2 Pseudoalteromonas sp. Gammaproteobacteria N/A CA; VA; EC 
#91_13 Pseudoalteromonas sp. Gammaproteobacteria N/A CA; VA; EC 
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B01-7 Pseudovibrio sp. Gammaproteobacteria PKS-I BS 
B01-9 Pseudovibrio sp. Gammaproteobacteria PKS-I BS 
B01-77 Pseudovibrio sp. Gammaproteobacteria N/A BS; MRSA 
B02-8.1 Pseudovibrio sp. Gammaproteobacteria PKS-I BS; MRSA 
B02-9.1 Pseudovibrio sp. Gammaproteobacteria N/A BS; MRSA 
B02-10.a Pseudovibrio sp. Gammaproteobacteria N/A BS; MRSA 
B02-10.b Pseudovibrio sp. Gammaproteobacteria N/A BS; MRSA 
B02-10.c Pseudovibrio sp. Gammaproteobacteria N/A BS; MRSA 
B02-10.1 Pseudovibrio sp. Gammaproteobacteria N/A BS; MRSA 
B02-61 Pseudovibrio sp. Gammaproteobacteria PKS-I BS; MRSA 
N/A = Not Applicable; NA = No Activity; CA = Candida albicans; BS = Bacillus subtilis; VA = Vibrio anguillarum VF = Vibrio 
fisheri; MRSA = Methicillin-Resistant Staphylococcus aureus 
1.2. Target bacteria used for testing antimicrobial properties 
The selected targets used in this work are a clinical isolate of Candida albicans 
(filamentous yeast), an environmental strain of Escherichia coli (Gram-) and Bacillus 
subtilis ATCC 6633 (Gram+), all belonging to the LEMUP collection. 
Other targets used were Micrococcus luteus DSM 1790 (Gram+) Bacillus subtilis 168 and 
Chlamydia trachomatis D/UW-3/CX. Furthermore, there are four reporter strains of B. 
subtilis used for testing the mechanisms of action (Table 2). C. trachomatis are obligate 
intracellular parasites. For this reason, C. trachomatis requires a host for maintenance 
and to conduct assays, therefore, HEp-2 cells were also used. HEp-2 are a cell line 
derived from the Human Epidermoid carcinoma (HeLa). HEp-2 cells were previously 
grown using Dulbecco's Modified Eagle Medium. All these targets belonged to the 
collection of the Institut für Pharmazeutische Mikrobiologie. 
Table 2 – B. subtilis 168 reporter strains specifying the vectors present and the cellular target of each 
particular vector. 
Reporter Strain Vector Target 
B. subtilis 168 
pAC6-PypuA Cell Wall 
pAC6-PyorB DNA Synthesis 
pAC6-PyheI Protein Synthesis 
pAC6-PyvgS RNA Synthesis 
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1.3. Zebrafish as models for testing anti-obesity properties of extracts 
For this assay, due to time constrains only strains #91-36.1, #91-36.2, #118-20, B02-8,1, 
B02-61, B02-22.2, B02-78 and B02-79 were able to be tested. Strains #91-36.1, #118-
20, B02-8,1, B02-61, B02-22.2, B02-78 were chosen for possessing either PKS-I or 
NRPS genes. Strain #91-36.2 was included due to its good results in the antimicrobial 
assays, even though this strain lacked any PKS-I or NRPS genes. Additionally, strain 
B02-79 was also able to be added to the testing. 
 
Fig 1 - Adult zebrafish swimming in an enclosed pen on the nursery aquarium with eggs on the bottom of 
the aquarium. Female zebrafish can be distinguished from males by the shape of their upper body, with 
females having a significantly larger abdomen giving them a more of a teardrop shape while male zebrafish 
are torpedo-shaped, with a smaller abdomen. 
Anti-obesity properties of the selected strains were tested using zebrafish (D. rerio) 
larvae. To obtain the larvae, twenty individuals, ten males and ten females were first 
selected by size and collected from the stock at CIIMAR and separated into two different 
pens. Males and females can be differentiated by their body shape. Individuals were 
selected by size to validate the maturity of the individuals. Before collection, fish were 
feed generic aquarium fish feed. The day before collection, by the late afternoon, male 
and female adults were combined. The morning after, the eggs were collected and 
cleaned. Live eggs were placed on a five liters tank at 25ºC for hatching. Seventy-two 
hours after, the eggs hatched and larvae were collected on to a petri dish. Then they 
were washed from the egg shell and placed in forty-eight well plates with freshwater, 
seven per well. To avoid extreme size disparities between larvae that can skew results, 
larvae were sorted by size. 
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2. Media used for testing 
2.1. Media for maintaining target bacteria 
Different media were used to grow and maintain the bacteria. C. albicans, E. coli and B. 
subtilis ATCC 6633 were cultivated in petri dishes with Luria Broth (Table 3) at 37ºC in 
the dark. M. luteus and B. subtilis 168 were cultivated in petri dishes with Mueller-Hinton 
Broth (Table 3). While B. subtilis 168 was grown at 37ºC, M. luteus was cultivated at 
30ºC, all of them in the dark. All liquid cultures of target bacteria were shaked at 200 
rotations per minute (r.p.m).  
Table 3 - Media composition used for maintenance and assays with the target bacteria. 
Reagents 
Medium 
Mueller-Hinton Broth Luria Broth 
Units per liter 
Beef Extract Infusion 2.0 grams ⸺ 
Casein Hydrolysate 17.5 grams ⸺ 
Starch 1.5 grams ⸺ 
Tryptone ⸺ 10.0 grams 
Yeast Extract ⸺ 5.0 grams 
NaCl ⸺ 10.0 grams 
Deionized water 1000.0 mL 1000.0 mL 
Agar 16.0 grams 16.0 grams 
 
2.2. Media used for maintenance and growth of selected strains 
The selected strains used for extraction were all grown/maintained in petri dishes 
containing Marine Broth and incubated at 25ºC in the dark. All liquid cultures were also 
shaked at 200 r.p.m. while incubating (Table 4). The natural sea water used in the media 
described above was sampled off the coast in Matosinhos, Porto, Portugal. As part of 
the work done was performed in Bonn, Germany, which is approximately 300km from 
the nearest source of sea water (the North Sea, in the Netherlands), natural sea water 
was unavailable. For this reason, artificial sea water, using Sea Salts from SIGMA® was 
prepared. 
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Table 4 - Media composition used for maintenance of strains and their culture for extraction. 
Reagents 
Medium 
Marine Broth Nutrient Broth M13 Modified Broth 
Units per liter 
Peptone 5.0 grams 5.0 grams 0.25 grams 
Yeast extract 1.0 grams 1.0 grams 0.25 grams 
Tris-HCl ⸺ ⸺ 50.0 mL 
Deionized water ⸺ 1000.0 mL 10.0 mL 
1,2
Glucose solution (2,5%) ⸺ ⸺ 10.0 mL 
1,3
Vitamins solution ⸺ ⸺ 10.0 mL 
1,4
Hutner’s basal salts 
solution 
⸺ ⸺ 20.0 mL 
5
Natural sea water/artificial 
sea water 
1000.0 mL ⸺ 900.0 mL 
Agar 16.0 grams 16.0 grams 16.0 grams 
1Sterilized through a 0.22 µl pore filter and added to the medium after sterilization 
2 Solution prepared with sterilized water 
30,1 µg/mL cobalamin, 2.0 µg/mL biotin, 5.0 µg/mL thiamine-HCl, 5.0 µg/mL Ca-pantothenate, 2.0 µg/mL folic acid, 5.0 
µg/mL riboflavin and 5.0 µg/mL nicotinamide. 
4Cohen-Bazire et al. (1957) 
5 Sea water was previously filtered through a 0,45 µm pore filter 
 
2.3. Assessment of the effect of chemical and biological stress on the 
extracts 
Secondary metabolism in bacteria is often associated to the presence of stressful 
situations, like nutrient deprivation, osmotic stress and presence of competitors or 
predators. Because of this, several modifications to the growth media and conditions of 
the strains were tested. 
Nutrient Broth is a complex medium crafted with deionized water. For this, it was used 
to test the lack of salinity. Sea water contains 23.926 g/L of sodium chloride (NaCl), but 
it is usually rounded to 24 g/L (Kester et al., 1967). With this in mind, Marine Broth 
supplemented with NaCl to a concentration of 26 g/L, was used to test higher salt 
concentrations (Table 4). This represents an approximate 15 % increase compared to 
natural seawater. 
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To analyze the effect of limiting nitrogen and organic compounds, M13 Modified Broth 
was used. M13 Modified Broth is a much less chemically complex medium than Marine 
Broth and contains lower levels of available nitrogen for the cells (Table 4). 
To simulate the presence of potential competitors, strains were exposed to an autoclaved 
culture of Bacillus subtilis and Escherichia coli, in a 1:100 ratio in Marine Broth. 
3. Extraction protocols used throughout this work 
3.1. Extraction protocol using acetone and dimethyl sulfoxide 
This protocol was based on Graca et al, 2013. Incubation of the stains was done on a 
petri dish with Marine Broth for approximately three to five days at the usual conditions 
of 25ºC in the dark. Afterwards, 20 mL liquid cultures in Marine Broth were prepared for 
all thirty-three strains and incubated for five days. At the end of the incubation period, 
each culture was used to prepare four types of extracts. One was the aqueous phase 
extract (F) while the other three were organic phase extracts, designated as crude (C), 
pellet (P) and supernatant (S). For the aqueous phase extract, 2 mL portion of the culture 
were centrifuged at 13000 r.p.m. for five minutes and the supernatant collected, filtered 
and sterilized through a 0.22 µm cellulose acetate syringe filter. As for the organic 
extracts, an organic mixture made of 10% dimethyl sulfoxide (DMSO) in Acetone was 
premade. For the crude extracts, the organic mixture was added to a 2-mL portion of 
culture in a 1:1 ratio and incubated for one hour at 200 r.p.m. in the dark. For the two 
other organic extracts, the supernatant and the pellet, another 2 mL of culture was 
retrieved and centrifuged at 13000 r.p.m. for five minutes. The resulting supernatant and 
pellet were separated and the organic mixture was added in the same proportions as the 
previous organic extract and incubated in the same conditions for one hour. After the 1- 
hour incubation, 2 mL of the upper phase of all the three organic extracts were retrieved 
and placed in a 2 mL Eppendorf and dried overnight until half or more of the volume was 
desiccated. In the morning after, the volume of the pellet extracts was completed up to 
a volume of 1 mL with sterile deionized water. To increase both durability and to 
concentration of the extracts produced, lyophilization was performed and extracts were 
then stored at -20ºC. Prior to use, extracts were dissolved in 1 mL of DMSO. 
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Fig 2 - Twenty mL culture of strains ready for extraction after the 5 days incubation period. 
3.2. Extraction protocol using ethyl-acetate 
In the attempt to improve yields and thus inhibition effect of the extracts, a more powerful 
solvent was chosen. Ethyl-acetate is the ester of ethanol and acetic acid and has two 
main characteristics that facilitate the extraction of compounds: immiscibility in water and 
low boiling point, 77°C at atmospheric pressure or 9ºC at near vacuum (6,7 kPa). The 
immiscibility in water allows for a better separation of the aqueous phase from the 
organic, removing the need of lyophilizing the culture prior to extraction. The low boiling 
point allows for the use of softer conditions for drying the organic phase, thus avoiding 
damage of any compound extracted. 
For this extraction, cultures of the strains were again grown up to five days. At the end 
of the incubation period, ethyl-acetate was added twice to the cultures in a 1:1 ratio, 
mixed for thirty minutes in a separatory funnel and then phase separation was permitted 
to occur. The aqueous was discarded and the organic was collected. In higher scale 
extractions, since the separatory funnel maximum volume was 500 mL, ethyl-acetate 
and the cultures were mixed in a separate vial and only then transferred to the separatory 
funnel. The collected organic phase was then dried in a Rotavapor® R-100 from 
BUTCHI, a rotatory vacuum evaporator at 25ºC at 100 mbar. After the ethyl-acetate was 
completely removed, 2 mL of DMSO was added to the balloon to dissolve the solid 
residues that formed on the bottom of the balloon if the extracts were used for 
antimicrobial assays. The residue in the balloon was dissolved in 2 mL of methanol 
instead of DMSO if the extract was used for liquid chromatography. 
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Fig 3 – (A) Close-up of phase separation in a 500 mL culture extract with ethyl acetate on top and the 
aqueous phase on the bottom. (B) Example of the 500 mL separatory funnel. (C) Rotatory evaporator from 
BUTCHI used for drying organic extracts. 
3.3. AmberliteTM XAD16N resin extraction with ethyl-acetate 
AmberliteTM XAD16N, from MERCK, is a non-ionic resin specifically designed to adsorb 
and hold hydrophobic compounds up to 40,000 MW, and specifically antibiotics. For 
extraction with Amberlite, a two liters culture of the strain #91-36.2 was grown for the five 
days at 25ºC in Marine Broth with the mixture of autoclaved culture of Bacillus subtilis 
and Escherichia coli at 200 r.p.m. in the dark. At the third day of culture, previously 
autoclaved AmberliteTM resin was added to the culture, in a total of 30 g for the two liters. 
At the end of the incubation period, the resin was filtered out using cellulose filters. The 
culture was then centrifuged, and the pellet was collected and was extracted in the same 
fashion as used with the ethyl-acetate previously. To the resin, 300 mL of ethyl acetate 
were added and mixed for 1 hour. After this period, the resin was separated from the 
ethyl-acetate and was discarded. As previously referred, the ethyl-acetate was dried in 
the rotary evaporator, and the solid residue was dissolved in DMSO. 
 
Fig 4 - Amberlite XAD16N resin autoclaved and ready to be added to the culture. 
3.4. Extraction protocol using methanol and dichloromethane 
To test possible anti-obesity compounds produced by the selected strains, 100 mL of the 
strains selected for the assay were grown in Marine Broth at 25ºC, 200 r.p.m. in the dark 
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for five days. At the end of the incubation period, the cultures were centrifuged and the 
supernatant was place at -20ºC for later use. The pellet was lyophilized to remove any 
trace of water. To the dried pellet, 50 ml methanol were added and mixed vigorously for 
30 min. After the methanol was collected, the process was repeated for a second time. 
The methanol was collected and subsequently dried in the rotatory evaporator. The solid 
residue in the balloon was then dissolved in 3 mL dichloromethane (DCM) and place in 
previously weight vials. The vials were place in a fume hood and the DCM was dried 
overnight. Afterwards, the weight of the vials was recorded. The vials were stored at -
20ºC until further use. For the anti-obesity assay a concentration to be at a specific 
concentration of 10 mg/mL was used. DMSO was used as solvent. 
 
Fig 5 - Finished and dissolved extracts ready for use in anti-obesity assays. 
4. Preliminary anti-microbial screenings 
To assess the viability of production by the strains, the preliminary anti-microbial assays 
in liquid used by Graca et al (2013) and Graca et al (2015) were repeated. 
4.1. Growth curves of Candida albicans, Escherichia coli and Bacillus 
subtilis 
Firstly, growth curves for Candida albicans, Escherichia coli and Bacillus subtilis were 
performed. Using fresh plates of either Candida albicans, Escherichia coli or Bacillus 
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subtilis, overnight 10 mL liquid culture with Luria Broth was made and incubated at 37ºC 
with 200 r.p.m. . The next morning the optical density at 600 nm (OD600nm) of the overnight 
cultures were measured and a 1:100 ratio 100 mL Luria Broth culture was made using 
the previous overnight culture and incubated under the same conditions. The OD600nm of 
the 1:100 100mL culture was tested every thirty minutes and registered. Additionally, a 
sample was also taken, serially diluted up to a factor of 10-6 and seeded on a plate 
containing Luria agar, to see how many colonies forming units (C.F.U.) the culture 
possesses at the time. The plates we placed on an incubator at 37ºC and colonies were 
counted the day after. The growth curves for these three targets were performed in 
triplicates. 
When the OD600nm is plotted against the time, a curve with three phases appear. The first 
one is the lag phase, the second one is the exponential phase and finally the third one 
is the stationary phase. When the OD600nm values between the second phase are 
logarithmized, the duplication time and an equation relating C.F.U.s to time for the 
microorganism was obtained. 
4.2. Antimicrobial liquid assays 
Similarly to Graca et al (2013), Greiner Bio-One 96-well plate were incubated overnight 
with each well containing 90 µL of culture of each target standardized to 2.5×105 and 
completed with 10 µL of each extract in triplicates. Moreover, 100 μL of each target 
organism were also grown to assess total growth of the microorganisms. Positive 
controls used were also done in triplicates. The OD600nm of plates was measured and 
then incubated for 24h at 37ºC in the dark. After the incubation period, OD600nm was again 
read. Analysis of inhibition of growth of the target microorganism was calculated, using 
the following formulae. 
ODR = AbsF − AbsI 
ODR= Optical density of each replica; AbsF= Absorbance value after 24h incubation; AbsI= 
Absorbance value prior to incubation. 
?̅?𝐸𝑥𝑡 =
𝑂𝐷𝑅1 + 𝑂𝐷𝑅2 + 𝑂𝐷𝑅3
3
 
?̅?𝐸𝑥𝑡= Mean optical density for each extract. 
%𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑒𝑥𝑡𝑟𝑎𝑐𝑡 = 100 −
?̅?𝐸𝑥𝑡
?̅?𝐶
∗ 100 
?̅?𝐶= Mean optical density of the control negative control 
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Inhibition of growth above 20% was considered as a positive result. 
5. Modified Kirby-Bauer assays 
Using the same extraction protocol used in the liquid assays, another batch of extracts 
was tested. The inhibition assay in solid performed here is a modified Kirby-Bauer assay, 
in which Mueller-Hinton Broth is seeded with the desired number of target cells and a 
drop of extract is placed on the surface and incubated at 37ºC, or 30ºC for M. luteus, 
overnight. For this assay, the initial targets chosen were M. luteus and B. subtilis, as 
these bacteria are sensitive to low concentrations of antibiotics, thus making it easier to 
detect any antimicrobial activity by any extract.  
As in the liquid assays, target cultures were grown overnight in Mueller-Hinton Broth 
liquid, at 200 r.p.m. and 30ºC for M. luteus or 37ºC for the other targets. The following 
morning, OD600nm was read. To allow standardization, the following equation is used to 
seed the media to 0.5 McFarland: 
  
Volume of medium [mL] ∗ 107
OD600nm ∗ (2.0 ∗ 109)
 
And since we are using 40 mL rectangular NuncTM OmniTrayTM plates, the equation could 
be simplified to: 
   
1
5 × OD600nm
 
When regular circular petri dishes are used, which can only contain 20 mL instead of 40 
mL, we can simply halve the result obtained by the previous equation. After the media 
was seeded, and using the Liquidator™ 96 pipette from Mettler-Toledo Rainin, forty-eight 
10 µL droplets were seeded in chess-like pattern the plate, to provide adequate spacing 
between droplets. After overnight incubation, inhibition halos were examined and 
compared to the control. Positive control used was Ampicillin, at 0.1 µg/mL for 
Micrococcus luteus and Bacillus subtilis. 
5.1. Direct cultures assay 
To determine if cultures were still able to produce inhibition of growth on targets 
independently from extraction methods, direct interaction between strains and targets 
was performed. For this, 20 mL cultures of the strains were grown in Marine Broth for 
three days. Identically to what was done in the modified Kirby-Bauer assay, plates of 
Mueller-Hinton Broth were seeded with the targets. After the media was seeded, 10 µL 
of cultures were directly placed on top of the agar, forty-eight at a time using the 
Liquidator™ 96 pipette for evenly distributed space around the droplets. Plates were 
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placed at 30ºC, an intermediate temperature between the 25ºC and 37ºC, the optimal 
growth temperatures for the strains and targets, respectably, for three days. After the 
incubation period, plates were examined for signs of inhibition. 
5.2. Well assay 
The modified Kirby-Bauer assay has the drawback that only 10 µL of extract can be used 
for testing on the media surface and still allow for the detection of inhibition halos. This 
can be a problem if the production of antimicrobial metabolites is small or if the extract 
protocol was not able to sufficiently retain enough compound to achieve inhibition.  
Therefore, to bypass these problems, wells were made in the testing plate. These wells 
allow up to 100 µL of extract to be tested, while also permitting a more evenly spaced 
area between droplets than if 10 µL were placed by hand. Positive controls used were 
again Ampicillin, at 0.1 µg/mL for M. luteus and B. subtilis. 
5.3. Diffusion assays with filter disks 
To prevent both evaporation and diffusion complications on possible antimicrobial 
compounds in the extracts that may conceal their action in the modified Kirby-Bauer 
assays, a new assay was devised. Comparably to assays done before, target cultures 
were grown overnight and seeded, using the same formula, in Mueller-Hinton broth with 
0.6% agar instead of the normal 1.6%. To add rigidity to the media, before placing this 
layer, a first coating with 1.6% agar Mueller-Hinton was made on the petri dish. Sterilized 
filter discs were then placed above the surface of the agar and filled with 100 µL of each 
extract. Positive control was Ampicillin at 1 mg/mL. Negative controls used were DMSO 
or methanol, depending on which one was used as solvent. For both controls, filter discs 
were filled with 10µL of the respected solvent. Finally, and like in the previous assays, 
plates were incubated at 37ºC for twenty-four hours. Plates were examined for inhibition 
halos around the discs. 
5.4. Modes of action of the extracts 
For the modes of action (MoA) assays, the reporter strains of Bacillus subtilis 168 (Table 
2) were used. These strains were genetically engineered with plasmids containing a set 
of promotors that can identify which one of the four main biosynthesis pathways has the 
extract or compound affected. The promotors used were PypuA for cell wall, PyorB for 
DNA synthesis, PyvgS for RNA synthesis and PyheI for protein synthesis. These 
promotors are attached to a copy of the LacZ gene on the pAC6 vector plasmid. LacZ 
encodes for the a β-galactosidase, which can hydrolyze X-Gal into galactose and the 
indigo blue compound, 5-bromo-4-chloro-3-hydroxyindole. So, when an extract is being 
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tested, if the extract damages one of the four biosynthesis pathways, the corresponding 
promoter is activated. Following its activation, the LacZ gene is transcribed and any X-
Gal incorporated by the cell from the medium is hydrolyzed and a dark blue hue is 
created, indicating the effect of the extract on the pathway. 
For the assay, the four reporters were grown overnight at 37ºC and 200 r.p.m. in Mueller-
Hinton Broth containing 5 µg/mL chloramphenicol until the OD600 reached 0.5 to 1. The 
five different strains were incorporated in Mueller-Hinton agar supplemented with 5 
µg/mL chloramphenicol and X-Gal (80 µg/mL in reporters pAC6-PypuA, pAC6-PyorB, 
pAC6-PyvgS and 104 µg/mL in reporter pAC6-PyheI), using the same formula as the 
one used for the modified Kirby-Bauer assays. Ten µL of the extracts were then tested 
on the plates containing the five reporters. The plates were incubated at 37 ºC for twenty-
four hours and each assay was done in duplicate. Positive controls used were Ampicillin 
for cell wall, Rifampicin for RNA synthesis, Tetracycline for protein synthesis and 
Ciprofloxacin for DNA synthesis. 
6. Evaluation of anti-Chlamydia trachomatis activity 
Chlamydia trachomatis can alternate between the extracellular cell, infectious 
elementary body and the intracellular, non-infectious reticulate body throughout their life 
cycle (Bastidas et al., 2013) and are responsible for one of the most prevalent sexually 
transmittable diseases. Not only due to their intracellular nature, C. trachomatis is able 
to, under stress conditions, form persistent aberrant bodies. These aberrant bodies are 
much more resistant to stress, and even thought not showing signs of infection, C. 
trachomatis can reactivate after stressful conditions have disappeared. These two facts 
make C. trachomatis extremely difficult to treat. 
To evaluate the bioactivity of extracts against C. trachomatis, the following assay was 
performed. Two hundred µL of Hep2 host cell suspension was incubated in 96-well plates 
for forty-eight hours. Following the incubation period, 50 µL of C. trachomatis D/UW-
3/CX were added and infection was allowed for two hours at 37 °C and 5% CO2. At the 
end of the incubation period, the medium was replaced with 100 µL of fresh medium 
along with two dilutions of the #91-36.2 extract, one of 2.56 µL and another of 1.28 µL of 
DMSO and water. This dilution was done so that DMSO would not kill the host cells, as 
eukaryotic cells are susceptible to it. Afterwards, the cultures were incubated for 30 h at 
37 °C, 5% CO2 and then fixed with ice cold methanol for 5 min. Finally, the samples were 
stained using 100 µL of fluorescein-conjugated antibodies specific for chlamydial 
lipopolysaccharide (LPS), The “Pathfinder Chlamydia Conformation System” from 
BioRad, and incubated for 30 minutes. Cytoplasm was stained with Evans blue, as part 
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of the kit. Next, the cultures were stained with DAPI at 3 mg/mL for one minute and 
washed two times with PBS for 10 minutes each. The samples were then ready for 
analysis by fluorescence microscopy. 
7. Testing anti-obesity properties of extracts from selected strains 
To conduct the testing on the zebrafish larvae, a solution of salts was first prepared to 
accommodate the eggs. This egg water consists of marine sea salts dissolved in 
deionized water, up to a concentration of 60 µg/mL. The egg water was then mixed with 
Phenylthiocarbamide (PTU), to a final concentration of 200 µM. PTU inhibits 
melanogenesis in zebrafish by blocking tyrosinase-dependent steps in the melanin 
pathway (Karlsson et al., 2001) making the larvae transparent. Using a 1 mL syringe, the 
water in the wells where the larvae were placed previously was removed, leaving behind 
a dead volume of 125 µL. Unfortunately, during this step, larvae can be sucked by the 
syringe causing irreversible damage to the larvae. To the well were then added 625 µL 
of the egg water and PTU mixture in two 312.5 µL portions. Finally, 0.75 µL of extracts 
was added to the well. DMSO and Resveratrol were used as controls at the same 
concentration as the extracts (10 mg/mL). Each extract and controls were tested in 
duplicate. Twenty-four hours after the first exposure, the egg water in the wells was 
renewed following the previous steps. Fifteen µL of Nile red, a fluorescent dye that stains 
both membrane and intracellular neutral lipids, was also added. The larvae were again 
exposed for another twenty-four hours. At the end of this 48-hour period, the larvae were 
anesthetized with a solution of 0.3% tricaine, collected into a concave slide and arranged 
with the abdomen facing up. In this position, the fat reserves of the larvae were more 
visible. Fluorescence was induced on the Nile red using a Leica DM6000 microscope 
with an excitation wavelength of 552 nm. The images were saved for analysis of the 
fluorescence intensity were measured using the software ImageJ. 
The levels of the inhibitory capacity against lipid production and accumulation were 
calculated using the intensity of fluorescence of the Nile red in conjunction with any lipids. 
The mean intensity of the negative control larvae, exposed only to DMSO, was 
considered as 100% of lipid accumulation. Inhibitory capacity was established as the 
inverse of the lipid accumulation. Positive control larvae were exposed to resveratrol, 
that mimics dietary calorie restrictions, stimulating metabolic rates and thus show an 
abnormally low lipid buildup in the larvae and no fluorescence in the larvae is detected. 
7.1 Statistical treatment 
To assess whether the differences amongst the control group and the treatment groups 
was significant, one-way analysis of variance (ANOVA) test was done on the mean 
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intensity values. ANOVA test was done in Microsoft® Office Excel, with alpha level was 
set at 0.5. After ANOVA, the Dunnett’s test was also done to compare each of the of 
treatments with the DMSO control. The Dunnett’s test is a multiple comparison procedure 
(many-to-one comparison) to compare each of the treatments to the DMSO control. The 
Dunnett’s test was also performed in Microsoft® Office Excel. 
 
Fig 6 - Forty-eight well plate with (A) all hatched zebrafish larvae and close-up (B) of a well with 7 larvae in 
it. 
8. Gel permeation chromatography 
Extracts are complex mixtures of organic molecules. Due to their complexity, identifying 
the molecule that triggers the action seen in the assays can be complicated. Therefore, 
breaking down the extract into fractions with less complexity is the best option. To 
achieve this, gel permeation chromatography (GPC) was chosen. GPC is a type of size 
exclusion chromatography, that separates analytes based on size. GPC uses an organic 
solvent passing through a column packed with a gel, usually cross-linked polyacrylamide 
or agarose gel. 
For GPC, only the two more promising strains, #91-36.1 and #91-36.2 were chosen. Five 
hundred mL of each strain were incubated for 5 days at 200 r.p.m. with Marine Broth 
supplemented with the autoclaved E. coli and B. subtilis at 25ºC. After the incubation 
period, extraction with ethyl acetate was performed. After drying on the rotatory 
evaporator, solid residues in the balloon were dissolved with methanol. A sample for 
testing was taken and tested using the modified Kirby-Bauer assay. GPC was performed 
on these extracts. 
GPC was performed using a Sephadex® LH20 column, with a GILSON® pump at a 
velocity of 2 mL/min, with fraction collected every fifteen minutes, up to a total of 3 hours. 
The Sephadex® LH20 column was chosen as the stacionary phase as Sephadex® LH20 
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was specially designed for separating terpenoids and small weight peptides, the principal 
category of molecules produced in secondary metabolism. The solvent used was 
methanol. After GPC, every fraction was dried in the rotatory evaporator using 100 mbar 
at 25ºC, with the solid residues being dissolved in 2 mL of methanol with the exception 
of the first 2 portions that were discarded. Finally, every fraction was tested for 
antimicrobial activity using again the modified Kirby-Bauer assay. 
 
Fig 7 – Chromatograph used for GPC. (A) Gilson 307 pump running at 2mL/min. (B) Sephadex LH20 column 
used. 
Results and Discussion 
1. Preliminary antimicrobial assays 
All the preliminary antimicrobial assays were performed using fresh extracts from 2 mL 
cultures in acetone plus DMSO, except for extraction with ethyl-acetate which used 20 
mL of culture. 
1.1. Antimicrobial liquid assays in 96-wells plates 
Liquid antimicrobial assays in 96-wells plates seemed to show results consistent to the 
ones showed by Graca et al (2013) and Graca et al (2015). Most of the strains were able 
to inhibit growth the of Bacillus subtilis above the 20% level (Table 5). Several extracts 
from different strains induced an inhibition level above 50% and in general, the more 
effective extracts were the ones obtained from the cell pellet (P) (26 positive extracts). 
The less effective extracts were the aqueous ones (F), indicating that the majority of the 
molecules produced were more soluble in organic solvents. 
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In total 18% of culture filtrate (F) extracts, 58% of the crude organic extracts (C), 79% of 
the cell pellet organic extracts (P) and 48 culture supernatant organic extracts (S) were 
bioactive. Of these, 1 filtrate, 1 crude organic extract, 10 pellet organic extracts and 1 
F = Aqueous phase extract; C = Crude organic extract; P = Pellet organic extract; S = Supernatant organic extract. 
Positive hits (more than 20% inhibtion) highlighted in green. 
Table 5 – Levels of inhibition produced by the 33 bacterial extracts against the 3 targets. 
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supernatant organic extract were above the 50% level of activity against B. subtilis. For 
strains SM 116 and B01-119c, all the extracts were positive regarding bioactivity. These 
preliminary results seemed to indicate a good bioactive potential of the strains screened, 
showing promising capabilities. 
Even though high bioactivities were obtained against B. subtilis, Candida albicans and 
Escherichia coli showed no signs of inhibition. These results may be explained by two 
factors: 1) the high sensibility of B subtilis to antimicrobial compounds (Adimpong et al., 
2012), especially when compared to the E coli used in this study, an environmental strain 
which has revealed high resistance in various antimicrobial screening (Graca et al., 2013; 
Graca et al., 2016; Graca et al., 2015), and 2) the need for extraction protocol refinement, 
because extracts might have possessed an insufficient concentration of bioactive 
molecules for detecting inhibition. 
1.2. Modified Kirby-Bauer assays 
This assay is the more traditional assay to determine both antimicrobial resistance and 
to test effectiveness of extracts and newly developed bioactive molecules. Due to the 
previous lack of inhibitions in both E. coli and C. albicans, these targets were not tested 
in this assay. The selected targets were B. subtilis and Micrococcus luteus, another 
Gram+ bacterium. B subtilis was chosen based on the preliminary results and M. luteus 
was chosen for its sensibility to bioactive compounds (Dischinger et al., 2009). However, 
similar extract to the previous ones assayed in 96-well plates did not induced inhibition 
(Fig. 8). 
 
Fig 8 – Kirby-Bauer assay of Acetone plus DMSO extracts from several bacteria against M luteus (A) and 
B. subtilis (B). The control used (C) was ampicillin at 0.1 mg/mL. No extract from the 33 strains showed 
inhibition 
To validate these results, this assay was repeated twice and similar results were 
obtained. The lack of bioactivity by these strains was not in agreement with the 
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preliminary results in 96-well plates and the genetic potential of the chosen strains as 
previously reported (Graca et al., 2013; Graca et al., 2015). 
1.2.1. Well assays with Acetone plus DMSO extracts 
As no inhibition was detected with 10 µL droplets of extract, 100 µL of each extract (in 
total 132 from the 33 bacteria) were tested using the well assays. With 10-fold increase 
of overall extract, it was expected to find bioactivity at least in some extracts. 
 
Fig 9 - Example of two plates of M. luteus used in the well assay where 100 µL extract were used. (A) 
Extracts from 2 mL culture in Acetone plus DMSO. (B) Extracts from 20 mL culture obtained with ethyl-
acetate. 
However, even with the higher volume of extract used, no inhibition halos were detected 
for any of the strains screened against B. subtilis or M. luteus (Fig 9 A). 
1.2.2. Disk assay using Acetone plus DMSO extracts 
The diffusion effectiveness in a given agar mesh decreases with the increase of the 
molecular weight of the diffusible molecules (Lebrun & Junter, 1993). To bypass any 
diffusion problem that might have occurred in the two previous assays, the agar 
concentration in the media was decreased from 1.6% to 0.6%. To avoid the drawback of 
loss of rigidity and structural integrity of the media, which in turn could impact the results, 
a second, more rigid layer of media was placed below the softer layer. Using fresh 
acetone plus DMSO extracts of 2 mL of culture, filter disks were soaked with 100 µL 
extract and placed on top of the media with a lower concentration of agar. Despite all the 
modification to the assay, inhibition halos were not detected (Fig 10).  
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With all possible variations done to the assays and inconsistency or lack of bioactivity 
results obtained so far, other variables like extraction solvent or stress inducing agents 
were tested for the obtainment or production of bioactive molecules. 
 
Fig 10 – Two examples of the disk assay performed with two media layers (1.6% and 0.6% agar) against B. 
subtilis (A) and M. luteus (B). The control used (C) was ampicillin at 0.1 mg/mL. No extract from the 33 
strains showed inhibition. 
1.2.3. Modified Kirby-Bauer assays of 20 mL culture ethyl-acetate 
extracts 
 
Fig 11 – Kirby-Bauer assay of Acetone plus DMSO extracts from several bacteria against M luteus. The 
control used (C) was ampicillin at 0.1 mg/mL. No extract from the 33 strains showed inhibition. 
It was then decided to change the extraction protocol. So, extracts were done using 20 
mL of culture instead of 2 mL, a 10-fold increase in concentration and instead of acetone 
plus DMSO, ethyl-acetate was used as solvent. 
As the lack of bioactivity of all the extracts assayed persisted (Fig 9 B and 11), it was 
hypothesized that the strains could have changed their secondary metabolism and 
stopped or decreased their production of bioactive molecules. 
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1.2.4. Direct culture assays 
To guarantee that bacterial strains were still fit to produce antimicrobial compounds in a 
non-extracted way, it was decided to co-culture them with the different targets. Culturing 
them in Mueller-Hinton medium was also making stress on bacteria, as Mueller-Hinton 
is a salt-less medium. 
 
Fig 12 – Co-culturing assay where 31 bacterial strains were cultivated for 3 days in Mueller-Hinton medium 
with targets incorporated. (A) Plate of B. subtilis. (B) Plate of M. luteus. 
However, the co-cultured strains were not effective in producing any visible sign of 
inhibition in B. subtilis (Fig 12 A). M. luteus unfortunately did not grow normally, 
producing unusually transparent colonies instead of the normal yellow. Regardless, M. 
luteus did not demonstrated any sign of inhibition (Fig 12 B). 
1.2.5. Potentiation of bioactivity production by biological stress 
In order to stimulate secondary metabolism and subsequent production of defense 
molecules, all the strains (Table 1) were cultured in 20 mL cultures supplemented with 
autoclaved B. subtilis and E. coli. Extracts were made using the acetone plus DMSO 
protocol. 
 
Fig 13 - Kirby-Bauer assay of 48 Acetone plus DMSO extracts B. subtilis showing two inhibition halos ((A) 
Extract #91-36.2 F. (B) Extract #118-20 F. Arrow points to possible mixing of the extracts). The control used 
(C) was ampicillin at 0.1 mg/mL. 
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Fig 14 – Well assay of extract #91-36.2 F and extract #118-20 F and mixture of the two extracts. (A) Plate 
with B. subtilis. (B) Close up of extract #118-20 F. (C) Close up of extract #91-36.2 F. (D) Close up of mixed 
extracts. (E) Close up of extracts #91-36.2 F and #118-20 F from the previous plate (arrow points to possible 
mixing of the extracts). 
Inhibition halos were detected for extracts #91-36.2 from the filtrate of the culture (F) and 
#118-20 F (Fig. 13), but the two extracts mixed in the plate (see arrow in Fig. 13). To 
undoubtedly validate these two bioactivities, the two extracts were screened 
independently and in a mixture of 1:1. The extracts volume was increased 10-fold. 
Inexplicable, the previous results were unable to be reproduced, even using 10 times 
more extract (Fig. 14). 
1.2.6. Induction of bioactivity by chemical stress 
Three different incubation conditions of all bacterial strains were evaluated on the 
production of bioactive compounds. A 15% increase on NaCl in the Marine Broth medium 
(salt stress) was tested to potentiate induction of bioactive molecule production. 
Cultivation using non-saline Nutrient Broth was also performed (osmotic stress). 
Furthermore, the effect of lower levels of nutrients compared to Marine Broth on bioactive 
production was tested using M13 Modified Broth (Marine Broth: 5% of peptone and 1 % 
of yeast extract. M13 Modified Broth: 0.25% of peptone and 0.25% of yeast extract). Two 
mL of culture were used for the extraction with Acetone plus DMSO. 
 
Fig 15 – Kirby-Bauer assay of 48 acetone plus DMSO using cultures grown in Nutrient Broth (osmotic stress) 
extracts against M luteus (A) and B. subtilis (B). The control used (C) was ampicillin at 0.1 mg/mL. 
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All strains were able to grow under all these conditions, however no bioactivity was 
observed for any of the extracts from all the stress conditions evaluated (Fig. 15). 
2. Assays with higher extraction volumes in ethyl-acetate 
2.1 Modified Kirby-Bauer assays 
As overall almost no bioactivity was obtained with small-scaled cultures, it was decided 
to attempt higher extraction volumes. Passing from a 2 mL to 500 mL cultures, obtaining 
a 250-fold increase, it was expected to potentially guarantee a much higher 
concentration of the bioactive molecules extracted. The extraction protocol was also 
revised, being chosen the simpler and more efficient extraction with ethyl-acetate (Siek, 
1978). Using higher culture volumes, it comes with the drawback that only a smaller 
number of strains can be tested in a reasonable timeframe. 
 
Fig 16 - – Kirby-Bauer assay of DMSO extract #91-36.2 using 500 mL of culture and ethyl-acetate for the 
extraction against B. subtilis (A) and M. luteus (B). The control used (C) was ampicillin at 0.1 mg/mL. Extract 
#91-36.2 sucessfully inhibited growth of both B. subtilis and M. luteus. 
 
Fig 17 - – Kirby-Bauer assay of DMSO extracts #91-36.1 and #91-36.2 using 500 mL of culture and ethyl-
acetate for the extraction against B. subtilis (A). The control used (C) was ampicillin at 0.1 mg/mL. Both 
extracts #91-36.1 and #91-36.2 sucessfully inhibited growth of B. subtilis. 
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Since the aqueous extract of #91-36.2 (F) showed antimicrobial bioactivity in the 
potentiation of bioactivity production by biological stress (see section 1.2.5), this strain 
was initially chosen. Incubation was done in 500 mL of Marine broth supplemented with 
autoclaved B. subtilis plus E. coli cultures, to mimic conditions described in section 1.2.5 
(biological stress). After incubation, 500 mL of culture were extracted using the ethyl-
acetate protocol and the dried residue was dissolved in DMSO. Extracts were tested 
using 10 µL droplets on top of the agar. 
With this methodology the extract was able to produce inhibition halos on both B. subtilis 
and M. luteus (Figs. 16 and 17). Moreover, extracts remained bioactive, although less, 
after 2-week periods. Furthermore, strains #91-36.1 and B02-78 were also tested. These 
were chosen primarily by the presence of both PKS-I and NRPS genes in their genome. 
 
Fig 18 - Well assay of DMSO extract B02-78 using 500 mL of culture and ethyl-acetate against B. subtilis 
(A) and M. luteus (B). No inhibition was observed in either two targets. The control used (C) was ampicillin 
at 0.1mg/mL 
As shown in Figure 17, strain #91-36.1 was able to produce an extract with antimicrobial 
effects on B. subtilis. The extract from strain B02-78 had a bright orange/red color, which 
can be seen in Figure 18. The extract was tested using the wells assay protocol 
described in section 1.2.1. This strain did now show any inhibition against both B. subtilis 
and M. luteus, as can be seen in Figure 18. 
2.2. Mode of action assays 
The mode of action (MoA) assays allow, using specific targets (Table 2), the identification 
of the metabolic pathway through which a bioactive compound interacts with cells leading 
to their death or impairing their growth. The specific targets were B. subtilis PyorB 
reporter for DNA, B. subtilis Pyhel reporter for Protein, B. subtilis PypuA reporter for Cell 
Wall and B. subtilis PyvgS reporter for RNA. Due to time constraints, this assay was 
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performed using only extracts from strain #91-36.2. In a first trial, no development of 
color, even in the controls used was observed which, indicated, perhaps, that the X-Gal 
was either insufficient or was possibly decayed (Fig. 19). 
 
Fig 19 – Mode of action screening with B. subtilis PyorB reporter for DNA (A), B. subtilis Pyhel reporter for 
Protein (B), B. subtilis PypuA reporter for Cell Wall (C) and B. subtilis PyvgS reporter for RNA (D). 
 
Fig 20 - Mode of action screening with B. subtilis PypuA reporter for Cell Wall with positive result circled in 
red. Arrow points to bluish coloration around the control. The control used was ampicillin at 0.1m mg/mL. 
In a second attempt, where fresh X-Gal was used, a faint but noticeable blueish 
coloration appeared in the place where the 10 µL droplet was placed (Fig. 20). As it was 
evident with strain B. subtilis PypuA, the extract is effective against the cell wall. No blue 
color was noticed in any of the other three reporters. 
3. Anti-Chlamydia trachomatis activity of ethyl-acetate extracts from 
#91-36.2 
Once again and due to time constrains, the search for bioactivity against Chlamydia 
trachomatis was only done with extracts from strain #91-36.2. 
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Fig 21 – Assays performed with HEp-2 cells. (A) Infected HEp-2 cells with C. trachomatis. (B) Infected HEp-
2 cells with C. trachomatis treated with Ciprofloxacin at 1.0 µg/mL. (C) Uninfected HEp-2 cells. (D) HEp-2 
cells infected with C. trachomatis treated with 1.28 µL of #91-36.2 extract. (E) HEp-2 cells infected with C. 
trachomatis treated with 1.28 µL of DMSO. 
The uninfected HEp-2 cells did not stain with the fluorescein-conjugated antibodies 
specific for chlamydial lipopolysaccharide (LPS) as they do not possess C. trachomatis 
intracellularly (Figs. 21 C; 22 C). When HEp-2 cells were infected with C. trachomatis 
they showed an intense green labelling because of the fluorescein-conjugated antibodies 
attached to the chlamydial LPS on the cell surface (Figs. 21 A; 22 A). When infected 
cells were treated with Ciprofloxacin, no green labelling was visible, because the 
chlamydial infection was controlled (only small dots of the remaining infection could be 
seen) (Figs. 21 B; 22 B). When infected HEp-2 cells were treated with 1.28 µL of #91-
36.2 extract, chlamydial aberrant bodies formed, indicating that the extract was inducing 
stress on Chlamydia. Under this volume (1.28 µL), no effect was visible due to cell 
incubation with DMSO (the #91-36.2 extract solvent) (Fig 21 E). When the infected HEp-
2 cells were treated with a higher volume of #91-36.2 extract (2.56 µL) a strong reduction 
of Chlamydia inside the HEp-2 cells was observed. The small labelling dots that could 
be seen (Fig. 22 D) on the cells treated with this extract were comparable to the ones 
seen after treatment with ciprofloxacin (Fig 21 B, 22 B). These results seem indicative of 
anti-chlamydial activity of strain #91-36.2. However, as DMSO in the same concentration 
(2.56 µL added) also induced a decrease of infection as well as of the production of 
FCUP 
Analysis of secondary metabolism in marine Actinobacteria: searching for novel compounds. 
38 
 
chlamydial aberrant bodies, caution must be taken regarding the conclusions of these 
results. 
 
Fig 22 – Assays performed with HEp-2 cells. (A) Infected HEp-2 cells with C. trachomatis. (B) Infected HEp-
2 cells with C. trachomatis treated with Ciprofloxacin at 1.0 µg/mL. (C) Uninfected HEp-2 cells. (D) HEp-2 
cells infected with C. trachomatis treated with 2.56 µL of #91-36.2 extract. (E) HEp-2 cells infected with C. 
trachomatis treated with 2.56 µL of DMSO. Chlamydial aberrant bodies were formed with this treatment. 
4. Gel permeation chromatography (GPC) of #91-36.1 and #91-36.2 
extracts 
Extracts are characteristically extremely complex mixtures of different molecules, with 
the majority being comprised of primary metabolic products and a smaller amount of 
secondary metabolic products. To identify the constituents of the extracts capable of 
inducing inhibition it is required to fractionate the extracts, thus separating them into less 
complex mixtures and ultimately individual molecules. GPC has several advantages 
such as a good separation of large from small molecules with a minimal volume of eluate, 
good sensitivity and minimal loss of samples due to negligible interaction with the 
stationary phase (Skoog et al., 2007). This technique, combined with the Sephadex LH 
20 column seemed to be a good candidate for separation of the extracts. 
Extracts from #91-36.1 and #91-36.2 with biological stimulation were chosen for GPC. 
Since both extracts could inhibit both M. luteus and B. subtilis, fractions were tested only 
against B. subtilis. As the first two fractions corresponded with the initial volume of the 
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column and thus having no real bioactive relevance for testing, fractions testing started 
at fraction 3 (F3) and end in fraction 15 (F15).  
 
Fig 23 - Well assay with B. subtilis with fractions from GPC of extract #91-36.1. The control used was 
ampicillin at 0.1 mg/mL 
None of the fractions from both strains showed inhibition (Fig. 23). Probably these results 
are due to the dilution of the bioactive compound. 
5. Ethyl-acetate extraction with AmberliteTM XAD16N resin 
In view of the previous lack of bioactivity in GPC attempt, an extraction with an adsorption 
resin was assayed. AmberliteTM XAD16N is used to remove hydrophobic compounds up 
to 40,000 MW and separation of large organic molecules. As it has a high surface area, 
it increases its effectiveness on extraction. 
A 2-liter culture of strains #91-36.1 and #91-36.2 with biological stimulation was made. 
At the third day of incubation, 30 grams of AmberliteTM (1.5%) were added and collected 
after the 5 days incubation period using cellulose filters. The resin was then submerged 
in ethyl-acetate for 1 hour with shaking for extraction. The rest of the culture was then 
centrifuged and the cell pellet collected and extracted with ethyl-acetate. After dried, the 
residues from the extractions were dissolved in DMSO. The Kirby-Bauer assay of the 
four extracts against B. subtilis and M. luteus showed no inhibitory effects as shown for 
#91-36.2 (Fig. 24). Similarly, the extracts from strain #91-36.1 yielded do inhibitions 
against both B. subtilis or M. luteus. 
Although antimicrobial inhibition was observed in several times and various assays, it 
has not been constant over time. This made it impossible to isolate potential bioactive 
molecules besides inducing great frustration due to lack of results. 
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Loss of bioactivity by the screened strains may be due to (1) changes in their secondary 
metabolism for unknown reasons and (2) low levels of production of bioactive molecules 
under the conditions tested. 
 
Fig 24 – Kirby-Bauer assay of extracts #91-36.2 from 2-liters of culture using AmberliteTM and the cell pellet 
with ethyl-acetate against B. subtilis (A) and M. luteus (B). No inhibitions were observed in both targets. The 
control used (C) was ampicillin at 0.1 mg/mL. 
6. Anti-obesity activity from extracts of selected strains 
Parallelly to the screening of the strains for new antimicrobial molecules we had the 
opportunity to screen for molecules with the capacity to affect lipid metabolism. This 
screening is important due to the fact that a real pharmacological approach that is both 
safe and effective is needed to fight against obesity. 
The assay was performed with 8 of the 33 bacterial strains. The 100 mL culture methanol 
extracts after dried were dissolved in DMSO in a final concentration of 10 mg/mL. Their 
effect on zebrafish larvae was assessed with Nile Red after 2 days of exposure to the 
extracts. Larvae incubated with only DMSO (negative control) showed an intense red 
staining which was considered as the 100% level of lipid content (Fig 25 A and B). DMSO 
has low toxicity and is commonly used solvent in the fish embryo test (Kais et al., 2013) 
and as Jones et al showed, DMSO has no effect on lipid accumulation on zebrafish 
larvae. When larvae were treated with 10 mg/mL of Resveratrol no staining was visible 
in their bodies, showing a complete reduction of their lipid accumulation and 100% lipid 
inhibition (Fig 25 C and D, Fig 26). 
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Fig 25 – Zebrafish larvae under fluorescence (A, C, E) and contrast-phase microscopy (B, D, F). Negative 
control larvae, exposed only to DMSO (A, B). Larvae show a normal lipid buildup, situated mostly among 
the lower abdomen. Positive control larvae, exposed only to Resveratrol (C, D). Larvae do not show lipid 
buildup among the lower abdomen. Larvae exposed to extract B02-61 (E, F). Lipid accumulation in the 
abdomen is occurring although slightly reduced when compared to DMSO. 
FCUP 
Analysis of secondary metabolism in marine Actinobacteria: searching for novel compounds. 
42 
 
 
Fig 26 - Percentage of inhibition of lipid production and accumulation in zebrafish larvae. Error bars are 
representing standard error of the mean (in general n ≥ 5). ** represents significant differences between 
the treatments and the control (DMSO) (= p < 0.01). 
Zebrafish larvae treated with extracts from selected strains showed red staining of lipid 
drops in Figure 25 (E and F). This means that no total inhibition of the lipid accumulation 
was achieved by the extracts. However, six strains induced a reduction in larvae lipid 
content (Fig 26). Despite this, only strains B02-79 and B02-61, showed a significant 
reduction of about 25% and 50% reduction, respectably. Statistical analysis showed 
these results to be statistically different from the control (F[8,65] = 6.98; p < 0.001). No 
effect on lipid production was observed with extracts for strains #91-36.2 and #118-20 
(Fig. 26). 
Although a complete inhibition of the lipid production was not obtained with the bacterial 
extracts, we could achieve a significant lipidic reduction. These results are very 
promising, suggesting that further studies should be done with increased concentration 
of our extracts. Subsequent extract fractionation would allow the isolation of the bioactive 
compound. Due to time constrains, this could not have been done. 
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7. Overall discussion 
The bacteria used in this work (17 strains of Actinobacteria, 15 strains of 
Gammaproteobacteria and 1 strain of Firmicutes) belong to phyla known for their 
potential to produce bioactive compounds (Aleti et al., 2015; Holmström & Kjelleberg, 
1999; Radjasa et al., 2007). They were chosen based on their previous bioactive 
potential as well as by their genetic potential in secondary metabolism production (Graca 
et al., 2013; Graca et al., 2015). They have the presence in their genomes of PKS-I and 
NRPS genes. These are responsible for many biosynthesized compounds of interest. 
PKSs are a family of enzyme complexes that catalyze polyketides by extending linear 
carbon extensions, similarly to fatty acid biosynthesis (Dutta et al., 2014). NRPS, 
similarly to PKSs, are a cluster of modular enzymes. NRPSs on the other hand 
synthesize peptide products, through complex regiospecific and stereospecific reactions 
and using a variety of proteinogenic and non-proteinogenic amino-acids (Strieker et al., 
2010). Both these genes are arranged in a single operon with different modules. 
Furthermore, the tested bacteria showed initially in this study, a good bioactive potential 
in the small-scale screening in 96-well plates and based on all the data, we were 
confident to obtain a successful outcome in this study. However, several subsequent 
screenings gave contrary results, which made it impossible to reach the major goal of 
this thesis. 
Several kinds of antimicrobial screenings and extraction protocols were tested in order 
to overcome the lack of consistent results. Increase of culture extraction volume resulted 
in an increased level of bioactivity and ethyl-acetate proved to be the best solvent. Ethyl 
acetate, the ester of ethanol and acetic acid, can extract nonpolar drugs quite efficiently. 
Additionally, ethers, like ethyl acetate are also hydrogen bond acceptor molecules being 
able to extract electron donor solutes. Ethyl-acetate is also relatively safe and 
inexpensive. These factors make ethyl-acetate one of the most versatile solvents and 
most used solvent for general purpose extractions (Siek, 1978). Ethyl-acetate is also one 
of the more commonly used organic solvents (Schulz et al., 1995; Selvameenal et al., 
2009; Zhang et al., 2015). Despite good results with ethyl acetate, future work must be 
done to refine the extraction protocol. These modification should include the testing of 
other solvents (or solvent mixtures, like MeOH/DCM) and conditions (for example, the 
effect of “salting-out”) (Siek, 1978). 
Using higher culture extraction volume, bioactivity against B. subtilis and M. luteus was 
achieved by strains Microbacterium foliorum (#91-36.2) and Rhodococcus equi (#91-
36.1). These results were encouraging. Unfortunately and unexpectedly, none of the 
medium modifications introduced (salt stress, osmotic stress and nutrient limitation) 
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stress favored bioactivity. Biological competition was somewhat able to favor bioactivity, 
although at the end its effect was lost. As the secondary metabolism is not necessary for 
the growth or survival of the producer, regulation is highly sensitive to the conditions 
stimulating their production. Because of this, medium composition is vital for the 
production of bioactive molecules (Bibb, 2005). It is also fundamental that when 
competing with other microorganisms, production levels of metabolites increase, to 
protect the producer from competitors (Firn & Jones, 2003). As such, when cultured in 
nutrient rich, osmotically balanced media or grow unchallenged by other 
microorganisms, wild-type bacteria do not produce any secondary metabolites or their 
production is reduced (Vining, 1990). 
R. equi is a soil-dwelling pathogenic actinomycete that can cause pulmonary infections 
specially in young foals (horses aged six months or lower) and immunocompromised 
humans. R. equi can be a facultative intracellular parasite of macrophages and its 
virulence is dependent on the presence of virulence plasmids. Despite the genus 
Rhodococcus being well known for its various applications, due to their extraordinary 
metabolic versatility and ability to biodegrade polyaromatic compounds and 
polychlorinated phenols and production of drugs and hormones (Ahmad et al., 1991; 
Yam et al., 2010), no antimicrobial bioactive secondary metabolite has been reported in 
the genus (McLeod et al., 2006). Nevertheless, several studies on the genus 
Rhodococcus, and in particular R. equi, show that it possesses a great genetic potential. 
Besides having the characteristically large genome of Actinobacteria, several strains of 
R. equi have numerous assemblies of both PKS-I and NRPS genes (Ayuso-Sacido & 
Genilloud, 2005; Doroghazi & Metcalf, 2013; McLeod et al., 2006). Rhodococci have high 
tolerance to stress, specifically desiccation (LeBlanc et al., 2008), fact that may justify 
the lack of bioactive stimulation by stressful conditions in our strain #91-36.1. The results 
obtained here indicate that R. equi might be indeed producing a bioactive metabolite. 
While first isolated from the phyllosphere of grass plants, M. foliorum, has also been 
found in other environments like marine sponges (Behrendt et al., 2001; Graca et al., 
2013; Graca et al., 2015). Although literature on the genus Microbacterium is scarce, M. 
foliorum contributes to aroma development in cheese during the ripening process 
(Deetae et al., 2009). Moreover, M. foliorum did not show any PKS-I or NRPS genes in 
their genome (Graca et al., 2013; Graca et al., 2015). Strain #91-36.2 of M. foliorum was 
able to inhibit B. subtilis and M. luteus. Furthermore, its extract seemed to have the ability 
to interfere with the cell wall. These results indicate that M. foliorum capacity to produce 
antimicrobial metabolites should be due to a gene different from a PKS-I or a NRPS. 
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Future work with these strains must include further genetic analysis, with a more 
complete characterization of the gene/genes responsible for this activity. Work must also 
focus on the constant obtainment of the bioactive molecules in enough quantity to induce 
inhibition, assess or confirm their mode of action, viability against other targets and 
isolation and characterization of the bioactive molecules. Regardless, the results 
achieved during this thesis are prove of the biotechnological potential that R. equi and 
M. foliorum possess. 
Somehow encouraging bioactivities were obtained against C. trachomatis. Once again, 
M. foliorum (strain #91-36.2) was bioactive against this intracellular parasite. 
Unfortunately, since DMSO also had a smaller but noticeable effect at the highest 
concentration tested, we must be careful regarding the conclusions of these results. At 
the lowest concentration tested, C. trachomatis developed aberrant bodies. Aberrant 
reticulate bodies contain non-dividing cells and continue to synthesize proteins and 
replicate DNA. The resulting inclusions of viable but nonculturable cells result in a 
prolonged infection (Hogan et al., 2004). This effect is undesirable, because C. 
trachomatis can fail to respond to antibiotic treatment while also leading to a long term 
phenotypic resistance to otherwise effective antibiotics (Wyrick & Knight, 2004). 
Combined to this, the emergence of homotypic antibiotic resistance in human 
Chlamydiae remains as a threat that requires the development of novel drugs active 
against this bacterium. However, since M. foliorum #91-36.2 is bioactive against C. 
trachomatis, M. foliorum seems to be a good candidate for searching for bioactive anti-
chlamydia molecules. Confirmation should be done by testing the extract in another 
solvent, to prevent the interfering seen with DMSO. 
Regarding the anti-obesity assay, Pseudovibrio sp. (B02-61) and Microbacterium sp. 
(B02-79) were bioactive against lipid accumulation in zebrafish. Zebrafish larvae are a 
very useful tool for identifying non-toxic small molecules for developing molecular 
therapeutics for treating clinical obesity (Jones et al., 2008). Obesity, already in 1995 
imposed a cost of $100 billion in the USA (Wolf & Colditz, 1996). Recent estimates 
suggest total annual economic costs associated with obesity over $215 billion 
(Hammond & Levine, 2010). Unfortunately, Resveratrol does not seem to show any 
adjuvant effect on energy restriction for obesity treatment purposes on humans (Alberdi 
et al., 2014). With all pharmacological approaches available today carrying safety 
concerns, including carcinogenic, cardiovascular, hepatotoxic, and psychiatric adverse 
effects (Hainer & Hainerova, 2012), newer therapy drugs are required. The results 
achieved by Pseudovibrio sp. and Microbacterium sp. make them promising candidates 
in the search for new anti-obesity bioactive compounds. Future work should focus in 
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obtaining refined fractions, with a higher concentration of bioactive compound to attempt 
a total inhibition of lipid accumulation. 
The work presented in this thesis opens the field for future approaches. Since we had 
limited time to perform the laboratory work, needed surveys to confirm results, isolate 
and characterization the metabolites behind these bioactivities are required. 
Conclusions 
This work showed that the bacteria tested demonstrated bioactivity that needs to be 
further explored and that to achieve effective bioactivity induction, an increasing in the 
culture extraction volume is required. Of the various solvents tested, ethyl-acetate was 
the most effective one. 
Antimicrobial activity of the Actinobacteria Microbacterium foliorum (#91-36.2) and 
Rhodococcus equi (#91-36.1) was observed against two Gram+ bacteria, B. subtilis and 
M. luteus. Microbacterium foliorum was also bioactive against C. trachomatis. 
Furthermore, extracts from Microbacterium foliorum showed to act by targeting the cell 
wall. 
The Gammaproteobacteria Pseudovibrio sp. (B02-61) and the Actinobacteria 
Microbacterium sp. (B02-79) were somehow effective in the reduction of lipid 
accumulation in larvae of zebrafish. 
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